1 of 1
Story summary
- Cosmo Pharmaceuticals announced that clascoterone demonstrated sustained hair growth and long-term safety in men with common pattern baldness after one year of use.
- The company notes that the results follow a year-long extension study and earlier late-stage data reported in December.
- In two large studies involving 1,465 men, the topical drug met its main goals.
- The same studies showed significant hair growth over six months.
